Annabidiol : 2nd Quarter Ending 6/30/2022 & Disclosure Statement

AnnaBidiol Corp. dba; First Harbor Capital

A Delaware Corporation

[phone]

For the Three and Six Months Ended June 30, 2022, and 2021

Prepared in accordance with

OTC Pink Basic Disclosure Guidelines

TABLE OF CONTENTS
	Page
Forward Looking Statements	3
Organizational Structure	3
Management	3
Balance Sheets as of June 30, 2022, and December 31, 2021	4
Statements of Operations for the Three and Six Months Ended June 30, 2022, and 2021	5
Statement of Stockholders' Equity for the Three and Six Months Ended June 30, 2022, and 2021	6
Statements of Cash Flows for the Six Months Ended June 30, 2022, and 2021	7
Notes to the Financial Statements	8
OTC Pink Basic Disclosures	11
Signatures	15

2

Forward Looking Statements

This Company Profile contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Statements made herein that may be considered forward-looking include statements incorporating terms such as "expects," "believes," "intends," "anticipates" and similar terms that relate to future events, performance, or results of the Company, including, without limitation, statements made regarding expected future results. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from management's present expectations or projections. These risks and uncertainties include, but are not limited to, customer and supplier relationships; prices; competition; ability to realize anticipated benefits from initiatives taken; market demand; litigation and other liabilities; and economic, political, governmental, and technological factors affecting the Company's operations, tax rate, markets, products, services, and prices, among others.

Organizational Structure

AnnaBidiol Corp. (the" Company" or "Asiana") was incorporated in the State of Delaware on Sept. 22, 2009, as DragonTel Holding, Inc. which thereafter changed its name to Asiana Dragons, Inc. The Company again changed its name to Strategic Pharma Information Sciences, Inc. on July 25, 2016, and then to AnnaBidiol Corp. effective upon FINRA approval on January 8, 2018.

Management

David D Peralta - Mr. Peralta was appointed interim Chief Executive Officer, President, and sole Director of the Company effective December 9, 2019.

3

ANNABIDIOL CORP. DBA; FIRST HARBOR CAPITAL

UNAUDITED BALANCE SHEETS

			June 30,				December 31,
			2022				2021
ASSETS
Current Assets
Cash		821				26,203
Total Current Assets		821				26,203
Total Assets
$	821	$	26,203
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable and accrued expenses	$	245,928	$	259,328
Total Liabilities		245,928				259,328
Commitments and Contingencies		-				-
Stockholders' Deficit
Preferred Series A, $0.0001 par value; 5,000,000 shares authorized, 500,000
shares issued and outstanding as of June 30, 2022, and December 31, 2021		50				50
Common Stock, $0.0001 par value; 495,000,000 shares authorized,
39,950,306 shares issued and outstanding as of June 30, 2022, and December
31, 2021			3,995				3,995
Subscription payable		20,000				20,000
Additional paid-in capital		5,265,625				5,265,625
Accumulated deficit		(5,534,777)				(5,522,795)
Total Stockholders' Deficit		(245,107)				(233,125)
Total Liabilities and Stockholders' Deficit	$	821			$	26,203

The accompanying notes are an integral part of these consolidated financial statements.

4

ANNABIDIOL CORP. DBA; FIRST HARBOR CAPITAL

UNAUDITED STATEMENTS OF OPERATIONS

For the Three Months Ended

June 30, 2022

June 30, 2021

For the Six Months Ended

June 30, 2022

June 30, 2021

Revenue	$	-	$	-	$	-	$	-
Cost of Goods Sold			-			-		-			-
Gross Profit			-			-			-			-
Operating Expenses:
General administrative			6,330			6,763		11,982			6,875
Professional and consulting fees			-			-		-			-
Travel			-			-		-			-
Total operating expenses			6,330			6,763			11,982			6,875
Loss from operations			(6,330)			(6,763)		(11,982)			(6,875)
Other Income (Expense)
Interest expense			-			-		-			-
Total other income (expense)			-			-		-			-
Net Loss Before Income Taxes			(6,330)			(6,763)		(11,982)			(6,875)
Income tax			-			-		-			-
Net Loss After Income Taxes
$	(6,330)	$	(6,763)	$	(11,982)	$	(6,875)
Weighted Average Number of Common Shares
Outstanding - Basic and Diluted			39,950,306			39,950,306			39,950,306			39,950,306
Loss per Common Share - Basic and Diluted
$	(0.00)	$	(0.00)	$	(0.00)	$	(0.00)

The accompanying notes are an integral part of these consolidated financial statements.

5